Article
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
International journal of cancer - 15 Jul 2013
Sano Takako, Takeuchi Shinji, Nakagawa Takayuki, Ishikawa Daisuke, Nanjo Shigeki, Yamada Tadaaki, Nakamura Takahiro, Matsumoto Kunio, Yano Seiji
Abstract excerpt
Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a critical problem in the management of patients with EGFR mutant lung cancer. Several mechanisms have been reported involved in this acquired resistance, including hepatocyte growth factor (HGF) activation of an alternative pathway. PI3K and mTOR are downstream molecules of receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.